MEMORY PHARMACEUTICALS COMPLETES PORTION OF ALZHEIMER'S STUDY

Memory Pharmaceuticals has completed the dosing portion of the safety and tolerability study of MEM 1003 in Alzheimer's patients.

The company also announced that it now expects to commence dosing patients with mild-to-moderate Alzheimer's disease in a Phase IIa clinical trial in the next several weeks. The Phase IIa proof-of-concept study for MEM 1003 will be a multicenter, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of MEM 1003 in patients with mild to moderate Alzheimer's disease.

The safety and tolerability study consisted of two segments -- a double-blind dose escalation phase and a double-blind treatment phase. In the first segment of the study MEM 1003 or placebo was administered to 49 patients two times on one day. Patients in this segment of the study were treated at escalating doses of MEM 1003 that reached 120 mg per dose. In the double-blind treatment segment, 32 patients received 120 mg of MEM 1003 or placebo twice daily for a period of 10 days.